Navigation Links
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/5/2008

TUSTIN, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 2:00 pm ET. The conference will be held at the New York Palace Hotel in New York City.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/conferences?id=19

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... California waste-to-energy firm claims first pl...eration, smallest footprint, salable pure gas, byp... (PRWEB) December 15, 2009 -- The ...tive organic waste-to-energy process will take pla...uary. , , ,This biowaste process known as VRAD&co...
(Date:11/30/2009)...vember 30, 2009 An international team of applied ...ETH Zrich have demonstrated compact, multibeam, an...e part of the light spectrum (infrared). By contra...ell-defined wavelength. The innovative multibeam l...o remote chemical sensing pollution monitoring, op...
(Date:11/30/2009)...Nov. 30 The Michael J. ...ay announced $1.5 million in total awards to six r...se-modifying therapies for Parkinson,s disease. Th...to Drug Discovery for Parkinson,s Disease program...plc (NYSE: ELN ), a neuroscience-based biotechno...
(Date:11/30/2009)...DAM, November 30 Biopharmaceutical...rst patients have been enrolled in its,multination...study is,designed to show reduction in transplant ...n allogeneic stem cell transplantation with a mism...ients eligible for an allogeneic,stem cell transpl...
Breaking Biology Technology:First Public Showing of Innovative Waste-to-Energy Process 2Scientists demonstrate multibeam, multi-functional lasers 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2
...alon, Inc. (Nasdaq:,CEPH) today communicated with ...e patient selection, dosing and administration for...ompany is sharing this information,with the medica...ng and use,of the medication. The letter, issued ...istration (FDA), was in response to recently repor...
..., Sept. 13 ,Exelixis, Inc. (Nasdaq: EXEL ) today ...000,000 shares of common stock. The net proceeds o...ter deducting estimated,offering expenses. All of ...xis. Exelixis has also granted the underwriter a 3...,000 shares of common stock. Goldman,Sachs & Co. a...
... executives from companies and government organiz...icine event produced by Burrill Life S...the foreseeable future a,trip to the doctor,s offi...t it is today. Armed with our complete genetic pro...the appropriate remedial therapies, even what,food...
Other Biology Technology:Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 2Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 3Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 4Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 5The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco 2
(Date:11/30/2009)... Researchers from LSU Health Sciences Center New ...river National Institute of Child Health and Human...lth, Brigham and Women,s Hospital, and Harvard Med...inking more than 5 servings of sugar- sweetened co...tly elevate the risk of developing diabetes during...
(Date:11/30/2009)...ratures continue to rise scientists are presented ...ecies respond and adapt. In a paper published in ...odriguez-Trelles and Dr Miguel Rodriguez assess th... of approximately 0.6˚C has already affected ...ng ecologists and evolutionary biologists is to pr...
(Date:11/30/2009)..., VILNIUS, Lithuania, Nov. 30 Neur...provider of high-precision biometric identificatio...he company,s core product line: VeriLook 4.0 Sof... and MegaMatcher 3.1 SDK for large-scale multi-b...systems (AFIS). Expanded capabilities in VeriLook ...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3How can scientists measure evolutionary responses to climate change? 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Material world 3A Graphenes versatility promises new applications 12967 1Material world 3A Graphenes versatility promises new applications 12967 2Material world 3A Graphenes versatility promises new applications 12967 3Material world 3A Graphenes versatility promises new applications 12967 4Blood vessel bends and branches put the brakes on statins 51290 1Blood vessel bends and branches put the brakes on statins 51290 2Blood vessel bends and branches put the brakes on statins 51290 3Blood vessel bends and branches put the brakes on statins 51290 4Blood vessel bends and branches put the brakes on statins 51290 5New theory gives more precise estimates of large scale biodiversity 9198 1New theory gives more precise estimates of large scale biodiversity 9198 2New theory gives more precise estimates of large scale biodiversity 9198 3
... circling your week-old peach has helped scientist...gshell formation. , The paradoxical finding gives...rmost protective eggshell layer forms as it points...s Dr. Ellen LeMosy, developmental biologist in the...d Graduate Studies. , Her research team named the...
...ren plain with the odd hydrothermal vent, the seaf...cording to a paper being published May 29 in Natur... along the mid-ocean ridge spreading system, repre...icrobes to colonize on Earth, said USC geomicrobio...uthor. , While seafloor microbes have been detect...
...- Throughout the overlooked depths of Lake Michiga...mal is rapidly disappearing. , Until recently, th...led Diporeia - was a major food source for commerc...ny prey fish upon which salmon, trout and walleye ...hods in a quest to explain their population freefa...
Other Biology News:Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3'Barren' seafloor teeming with microbial life 2'Barren' seafloor teeming with microbial life 3A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4
Mouse Anti-Human NR4A2 Monoclonal Antibody, Unconjugated, Clone 3E10 from Abnova Corporation
...em for detection of very low level of luminescent ...sensitive camera to detect low level light in anim...e research, gene expression, circadian rhythm or W...otor-driven camera inside the light-tight cabinet....
...lyzer and Sorter) large particle flow cytometers f...cytometry to applications that were not previously... and sorting. Our instruments are based on the sa...are designed to accommodate much larger objects, u...
Mouse Anti-Human LDB3 Monoclonal Antibody, Unconjugated, Clone 3C8 from Abnova Corporation
Biology Products: